Research use only · EU-warehoused · COA on every batch · HPLC ≥99% · Shipment 2–5 days
Log in Register
Home/ Catalogue/ Neuroprotective/ TB-500 (Frag)
In stock
TB-500 (Frag)

TB-500 (Frag)

Lyophilised · ≥99% (HPLC) ·

Quantity Volume discounts auto-applied
Custom quantity
1

Supplied lyophilised. Reconstitution typically uses bacteriostatic water.

Independently third-party tested · COA on every batch · 48h EU dispatch
[01]

Overview

Hidden inside a large repair protein is a tiny fragment that the body cleaves out and uses on its own. TB-500 (Frag) is the synthetic acetylated tetrapeptide Ac-Ser-Asp-Lys-Pro (Ac-SDKP, also called goralatide), a naturally occurring fragment released from thymosin β4. Rather than the full thymosin β4 molecule, this listing is the short Ac-SDKP sequence itself — one of the most studied antifibrotic and anti-inflammatory peptide fragments in the literature.

A fragment with a life of its own. Ac-SDKP is generated endogenously from thymosin β4 through the action of prolyl oligopeptidase and is regulated within the renin-angiotensin system, where angiotensin-converting enzyme (ACE) is a primary route of its degradation (Kassem et al., 2019). Because ACE inhibition raises Ac-SDKP levels, the peptide sits at an intersection of cardiovascular and tissue-remodeling biology, making it a focused tool for fibrosis research distinct from full-length thymosin β4.

What the research explores. The literature concentrates on anti-fibrotic and anti-inflammatory endpoints:

  • Organ fibrosis — reviews describe the Tβ4-POP-Ac-SDKP axis and its role across fibrotic processes in multiple organs (Wang et al., 2022).
  • Pulmonary fibrosis models — a meta-analysis examined Ac-SDKP inhibition of pulmonary fibrosis in animal models (Gong et al., 2023).
  • ACE inhibition and hypertension — work synthesizes Ac-SDKP's role in ACE inhibition and its relevance to hypertension and tissue injury (Kumar et al., 2018).
  • Cardiovascular signaling — studies probe the relevance of the Tβ4-Ac-SDKP pathway to the cardiovascular system (Kassem et al., 2019).

These findings derive from in vitro and animal research describing biological activity; they do not establish safety or efficacy in humans. Full citations are listed under the Scientific References tab.

Physicochemical profile. CAS 120081-14-3 · Molecular formula C₂₀H₃₃N₅O₉ · Molecular weight 487.5 g/mol · Sequence Ac-Ser-Asp-Lys-Pro · Appearance: white lyophilized powder · Soluble in water.

Specification & quality. Each individually sealed vial contains 2 mg of TB-500 (Frag) — Ac-SDKP — as a white lyophilized powder at ≥99% purity by HPLC. Every batch is third-party tested, with a Certificate of Analysis (COA) available. Store at −20 °C, protected from light and moisture.

This product is intended for laboratory research use only (RUO). It is not a drug, food, cosmetic, or dietary supplement, and is not for human or veterinary use, ingestion, or diagnostic application. Handling is restricted to qualified research professionals operating in an appropriately equipped laboratory.

Supplied for in-vitro laboratory research use only (RUO). Not a drug, food or supplement; not for human or veterinary use.

[04]

Quality & COA

Certificate of Analysis
Lot-specific COA with every order

Certificate of Analysis — lot-specific COA ships with every order and is available on request.

Each lot is tested by an independent third-party laboratory for identity (mass spectrometry) and purity (HPLC). The Certificate of Analysis for your specific batch ships with the order and is available on request — no house data, no exceptions.

HPLC purity
≥99% (HPLC)
Method
HPLC + MS
Endotoxin
Reported
[02]

Data Sheet

CAS number120081-14-3
Molecular formulaC₂₀H₃₃N₅O₉
Molecular weight487.5
SequenceAc-Ser-Asp-Lys-Pro
Purity≥99% (HPLC)
Physical formWhite lyophilized powder
Quantity2mg/vial
SolubilitySoluble in water
StorageStore at -20°C, protect from light
Shelf life24 months from manufacture date
OriginEU · Slovakia
ClassificationResearch use only
[03]

Scientific References

01 Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. PMID: 41966639. doi:10.1007/s40279-026-02437-0. PubMed 02 Mavrych V, Shypilova I, Bolgova O. Therapeutic peptides in gerontology: mechanisms and applications for healthy aging. Front Aging. 2026. PMID: 42021992. doi:10.3389/fragi.2026.1790247. PubMed 03 Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. J Am Acad Orthop Surg Glob Res Rev. 2026. PMID: 41490200. doi:10.5435/JAAOSGlobal-D-25-00236. PubMed 04 Di H, Huang J, Zhang D et al.. Thymosin beta 4: An emerging therapeutic candidate for kidney diseases. Peptides. 2026. PMID: 41570941. doi:10.1016/j.peptides.2026.171467. PubMed 05 Mayfield CK, Bolia IK, Feingold CL et al.. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. Am J Sports Med. 2026. PMID: 41476424. doi:10.1177/03635465251357593. PubMed 06 Gong HB, Zhang CM, Tang XY et al.. [Meta-analysis of Ac-SDKP inhibition of Pulmonary fibrosis in animal models]. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2023. PMID: 37248179. doi:10.3760/cma.j.cn121094-20211115-00565. PubMed 07 Liu AD, Yang F. [Review on biological effects and mechanism of Ac-SDKP]. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2023. PMID: 36882283. doi:10.3760/cma.j.cn121094-20220506-00238. PubMed 08 Wang W, Jia W, Zhang C. The Role of Tβ4-POP-Ac-SDKP Axis in Organ Fibrosis. Int J Mol Sci. 2022. PMID: 36362069. doi:10.3390/ijms232113282. PubMed 09 Cantero-Navarro E, Fernández-Fernández B, Ramos AM et al.. Renin-angiotensin system and inflammation update. Mol Cell Endocrinol. 2021. PMID: 33798633. doi:10.1016/j.mce.2021.111254. PubMed 10 Naicker K, Ntsekhe M. Tuberculous pericardial disease: a focused update on diagnosis, therapy and prevention of complications. Cardiovasc Diagn Ther. 2020. PMID: 32420111. doi:10.21037/cdt.2019.09.20. PubMed 11 Kassem KM, Vaid S, Peng H et al.. Tβ4-Ac-SDKP pathway: Any relevance for the cardiovascular system?. Can J Physiol Pharmacol. 2019. PMID: 30854877. doi:10.1139/cjpp-2018-0570. PubMed 12 Dadar M, Shahali Y, Chakraborty S et al.. Antiinflammatory peptides: current knowledge and promising prospects. Inflamm Res. 2019. PMID: 30560372. doi:10.1007/s00011-018-1208-x. PubMed 13 Ramasamy V, Mayosi BM, Sturrock ED et al.. Established and novel pathophysiological mechanisms of pericardial injury and constrictive pericarditis. World J Cardiol. 2018. PMID: 30344956. doi:10.4330/wjc.v10.i9.87. PubMed 14 Kumar N, Yin C. The anti-inflammatory peptide Ac-SDKP: Synthesis, role in ACE inhibition, and its therapeutic potential in hypertension and cardiovascular diseases. Pharmacol Res. 2018. PMID: 29990624. doi:10.1016/j.phrs.2018.07.006. PubMed 15 Vasilopoulou E, Riley PR, Long DA. Thymosin-β4: A key modifier of renal disease. Expert Opin Biol Ther. 2018. PMID: 29727205. doi:10.1080/14712598.2018.1473371. PubMed

References are illustrative of the research literature surrounding this compound. All claims relate to in-vitro and animal models only.

[05]

FAQ

TB-500 (Frag) is the synthetic tetrapeptide Ac-Ser-Asp-Lys-Pro (Ac-SDKP, also known as goralatide), a small fragment that the body cleaves from a larger thymosin β4 precursor and that acts on its own in research models. Condor Research supplies it as a 2 mg lyophilized vial at ≥99% HPLC purity, strictly for in-vitro laboratory research use only.

They are different molecules. TB-500 (Frag) is the four-residue Ac-SDKP (goralatide) tetrapeptide, whereas the standard TB-500 product is the much larger 43-residue actin-binding fragment derived from thymosin β4. The Frag isolates one short, naturally cleaved sequence rather than the full peptide. Condor Research offers each as a separate ≥99% HPLC, research-use-only reference compound, each with its own COA.

TB-500 (Frag) is the small Ac-SDKP tetrapeptide and is offered as a 2 mg vial, while the larger 43-residue TB-500 is supplied at 10 mg; the masses are analytical reference quantities for two distinct molecules, not doses. To compare value per mg or for current pricing, contact info@condorresearch.com. Both are ≥99% HPLC research-use-only materials.

TB-500 (Frag) isolates the single Ac-Ser-Asp-Lys-Pro (goralatide) sequence, a defined cleavage product, whereas full-length TB-500 is the 43-residue actin-binding fragment with broader structural features. Researchers choose the Frag to study that one short motif specifically. Both are supplied as separate ≥99% HPLC, research-use-only reference compounds; selection depends on your in-vitro research question.

TB-500 (Frag) is the Ac-SDKP tetrapeptide derived from thymosin β4 biology, while BPC-157 is a 15-residue gastric pentadecapeptide studied for cytoprotective mechanisms. They are both short peptides in regenerative research but have unrelated sequences and pathways. Condor Research offers each as a distinct ≥99% HPLC, research-use-only reference compound; the choice depends on your experimental target.

TB-500 (Frag) is selected when the focus is specifically the Ac-SDKP (goralatide) tetrapeptide as an isolated, naturally cleaved sequence, rather than the broader 43-residue thymosin β4 fragment. Researchers studying that short motif on its own choose the Frag. Both remain research-use-only reference materials with no human or veterinary application.

Yes. The acetylated tetrapeptide Ac-Ser-Asp-Lys-Pro (CAS 120081-14-3) is verified for each lot by an independent third-party laboratory using HPLC for purity and mass spectrometry for identity, confirming both the sequence and N-terminal acetylation. Results are documented on the batch-specific Certificate of Analysis, available on request at info@condorresearch.com.

Yes. TB-500 (Frag) is supplied strictly for laboratory research use only (in vitro). It is not a medicine, food, supplement, cosmetic, or medical device, and is not for human or veterinary use, administration, or consumption. Condor Research provides no dosing, protocols, or human-use guidance. Purchase is limited to qualified professionals and institutions aged 18 or over.

Yes. Each TB-500 (Frag) lot is tested by an independent third-party laboratory by HPLC for identity and purity, with mass spectrometry confirmation, and ships against a batch-specific Certificate of Analysis verifying ≥99% purity. To request the COA for the current lot before ordering, contact info@condorresearch.com.

For analytical laboratory preparation only, TB-500 (Frag) is water-soluble and can be reconstituted with a sterile aqueous diluent; with a 2 mg vial the chosen volume sets the working concentration. Store the sealed lyophilized vial at -20°C, protected from light, with a 24-month shelf life. This is laboratory handling information, not guidance for any human or animal use.

[06]

Reviews

Leave a review
Earn 250 points for a verified review (account required).
4.7
97 verified reviews
5
78%
4
16%
3
4%
2
1%
1
0%
Apr 2026
Trustworthy supplier

Identity by MS confirmed in our facility. Communication around storage and handling was precise and professional.

K. Wójcik · Research group · PL Verified purchase
Mar 2026
Reference-grade consistency

Reconstitution was clean with no visible particulates. The lot-specific COA matched the assay we ran in-house — purity is exactly as stated.

Dr. M. Hartmann · Research lab · DE Verified purchase
Mar 2026
COA matched our own HPLC

We verify every incoming compound by HPLC; this batch came back within tolerance of the certificate. Dispatch from the EU warehouse was quick.

L. Fischer · University group · AT Verified purchase
Feb 2026
Impeccable packaging

Cold-chain handling was respected end to end. Vials arrived sealed, labelled and intact. Documentation is the most thorough I've seen from an EU supplier.

Dr. S. Novak · Private lab · CZ Verified purchase
Jan 2026
Reliable, well documented

Solubility and stability were as described. Knocked one star only because express shipping options are limited, but quality is not in question.

P. Andersson · Research institute · SE Verified purchase

Related compounds